Table 1.
Baseline characteristics.
| Total (n) | 351 |
| Age (yrs) (mean ± SD) | 69.8 ± 10.5 |
| Sex (Male) (n, %) | 275 (78.3) |
| BMI (kg/m2) (mean ± SD) | 23.7 ± 3.7 |
| HTN (n, %) | 172 (49.0) |
| DM (n, %) | 88 (25.1) |
| Previous BCG (n, %) | 70 (19.9) |
| Previous TURB number (n, %) | |
| 0-1 | 237 (67.5) |
| ≥2 | 114 (32.5) |
| Tumor size (cm) | 4.11 ± 3.30 |
| Multiplicity (n, %) | 10 (2.8) |
| Grade (n, %) | |
| High grade | 343 (93.2) |
| Low grade | 5 (1.4) |
| T stage (n, %) | |
| T1-2 | 232 (66.1) |
| T3-4 | 116 (33.0) |
| N stage (n, %) | |
| N0 | 267 (76.1) |
| N1-2 | 58 (16.5) |
| Lymph node density (%) | 4.51 ± 13.9 |
| Preoperative lab | |
| Creatinine (mg/dL) | 1.18 ± 1.05 |
| eGFR (mL/min/1.73 m2) | 74.5 ± 26.9 |
| Urine pH | 6.06 ± 0.78 |
| Urine albuminuria (n, %) | |
| 0-1 positive (< 30 mg/dL) | 237 (67.5) |
| ≥2 positive (≥ 30 mg/dL) | 113 (32.2) |
| Neo-adjuvant chemotherapy (n, %) | 87 (24.8) |
| Adjuvant chemotherapy (n, %) | 55 (15.7) |
| Median follow up period (months) | 16.0 (5.9-24.8) |
| Median recurrence free survival (months) | 12.4 (4.9-24.3) |
| Median overall survival (months) | 15.8 (5.8-24.4) |
BMI, body mass index; eGFR, estimated glomerular filtration rate.